Edwards Lifesciences Marks 25 Years of Structural Heart Care in Thailand
Global medical innovator Edwards Lifesciences celebrates a quarter-century of operations in Thailand, focusing on advancements in heart valve disease treatment.
According to a report by Khaosod Online, Edwards Lifesciences (NYSE: EW) recently celebrated its 25th anniversary of operations in Thailand. Since establishing its local presence in 2000, the company has focused on structural heart disease innovation, collaborating with healthcare professionals, hospitals, and government agencies to improve treatment outcomes for patients with heart valve conditions.
The anniversary event, titled “One Edwards Thailand,” was held in September 2026 at the company’s office in the Silom Complex, Bangkok. Attendees included representatives from the U.S. Embassy, the American Chamber of Commerce in Thailand (AMCHAM), and various medical technology industry partners. The company reaffirmed its commitment to expanding access to medical innovations and supporting the ongoing development of Thailand’s public health infrastructure.
For residents and expatriates, this milestone highlights the continued investment in specialized cardiac care within the country. The presence of global medical firms often correlates with the availability of advanced diagnostic and surgical technologies in local hospitals. While the company has pledged to continue its support for clinical training and healthcare system development, specific details regarding new product launches or upcoming clinical partnerships remain to be confirmed. Patients seeking information on specific heart valve treatments should consult with their local healthcare providers or cardiologists to understand the current availability of these medical technologies in their specific region.
